Type I tyrosinemia: Difference between revisions
m (Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +)) |
mNo edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}}; {{AE}} | |||
{{Infobox_Disease | | {{Infobox_Disease | | ||
Name = {{PAGENAME}} | | Name = {{PAGENAME}} | | ||
Line 15: | Line 19: | ||
MeshID = D020176 | | MeshID = D020176 | | ||
}} | }} | ||
==Overview== | |||
'''Type I tyrosinemia''' is the most severe form of this disorder and is caused by a shortage of the [[enzyme]] [[fumarylacetoacetate hydrolase]] ({{EC number|3.7.1.2}}), encoded by the gene [[FAH gene|FAH]] found on chromosome number 15. Fumarylacetoacetate hydrolase is the last in a series of five enzymes needed to break down [[tyrosine]]. Symptoms of type I tyrosinemia usually appear in the first few months of life and include failure to gain weight and grow at the expected rate (failure to thrive), diarrhea, vomiting, yellowing of the skin and whites of the eyes ([[jaundice]]), cabbagelike odor, and increased tendency to bleed (particularly [[nosebleed]]s). Type I tyrosinemia can lead to [[liver]] and [[kidney]] failure, problems affecting the [[nervous system]], and an increased risk of [[Hepatocellular carcinoma|liver cancer]]. | '''Type I tyrosinemia''' is the most severe form of this disorder and is caused by a shortage of the [[enzyme]] [[fumarylacetoacetate hydrolase]] ({{EC number|3.7.1.2}}), encoded by the gene [[FAH gene|FAH]] found on chromosome number 15. Fumarylacetoacetate hydrolase is the last in a series of five enzymes needed to break down [[tyrosine]]. Symptoms of type I tyrosinemia usually appear in the first few months of life and include failure to gain weight and grow at the expected rate (failure to thrive), diarrhea, vomiting, yellowing of the skin and whites of the eyes ([[jaundice]]), cabbagelike odor, and increased tendency to bleed (particularly [[nosebleed]]s). Type I tyrosinemia can lead to [[liver]] and [[kidney]] failure, problems affecting the [[nervous system]], and an increased risk of [[Hepatocellular carcinoma|liver cancer]]. | ||
Worldwide, type I tyrosinemia affects about 1 person in 100,000. This type of tyrosinemia is much more common in Quebec, Canada. The overall incidence in Quebec is about 1 in 16,000 individuals. In the Saguenay-Lac-Saint-Jean region of Quebec, type 1 tyrosinemia affects 1 person in 1,846.<ref>{{cite journal |author=Grompe M, St-Louis M, Demers SI, al-Dhalimy M, Leclerc B, Tanguay RM |title=A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I |journal=N. Engl. J. Med. |volume=331 |issue=6 |pages=353–7 |year=1994 |pmid=8028615 |doi= |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=8028615&promo=ONFLNS19}}</ref> | Worldwide, type I tyrosinemia affects about 1 person in 100,000. This type of tyrosinemia is much more common in Quebec, Canada. The overall incidence in Quebec is about 1 in 16,000 individuals. In the Saguenay-Lac-Saint-Jean region of Quebec, type 1 tyrosinemia affects 1 person in 1,846.<ref>{{cite journal |author=Grompe M, St-Louis M, Demers SI, al-Dhalimy M, Leclerc B, Tanguay RM |title=A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I |journal=N. Engl. J. Med. |volume=331 |issue=6 |pages=353–7 |year=1994 |pmid=8028615 |doi= |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=8028615&promo=ONFLNS19}}</ref> | ||
==Historical Perspective== | |||
==Classification== | |||
==Pathophysiology== | |||
==Causes== | |||
==Differentiating {{PAGENAME}} from Other Diseases== | |||
==Epidemiology and Demographics== | |||
==Risk Factors== | |||
==Screening== | |||
==Natural History, Complications, and Prognosis== | |||
===Natural History=== | |||
===Complications=== | |||
===Prognosis=== | |||
==Diagnosis== | |||
===Diagnostic Criteria=== | |||
===History and Symptoms=== | |||
===Physical Examination=== | |||
===Laboratory Findings=== | |||
===Imaging Findings=== | |||
===Other Diagnostic Studies=== | |||
==Treatment== | |||
===Medical Therapy=== | |||
===Surgery=== | |||
===Prevention=== | |||
==References== | ==References== | ||
Line 27: | Line 73: | ||
{{Amino acid metabolic pathology}} | {{Amino acid metabolic pathology}} | ||
[[Category:Endocrinology]] | |||
[[Category: | |||
[[de:Tyrosinämie Typ I]] | [[de:Tyrosinämie Typ I]] |
Latest revision as of 20:19, 20 July 2016
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Type I tyrosinemia | |
Tyrosine | |
ICD-10 | E70.2 |
ICD-9 | 270.2 |
OMIM | 276700 |
DiseasesDB | 13478 |
eMedicine | ped/2339 |
MeSH | D020176 |
Overview
Type I tyrosinemia is the most severe form of this disorder and is caused by a shortage of the enzyme fumarylacetoacetate hydrolase (EC 3.7.1.2), encoded by the gene FAH found on chromosome number 15. Fumarylacetoacetate hydrolase is the last in a series of five enzymes needed to break down tyrosine. Symptoms of type I tyrosinemia usually appear in the first few months of life and include failure to gain weight and grow at the expected rate (failure to thrive), diarrhea, vomiting, yellowing of the skin and whites of the eyes (jaundice), cabbagelike odor, and increased tendency to bleed (particularly nosebleeds). Type I tyrosinemia can lead to liver and kidney failure, problems affecting the nervous system, and an increased risk of liver cancer.
Worldwide, type I tyrosinemia affects about 1 person in 100,000. This type of tyrosinemia is much more common in Quebec, Canada. The overall incidence in Quebec is about 1 in 16,000 individuals. In the Saguenay-Lac-Saint-Jean region of Quebec, type 1 tyrosinemia affects 1 person in 1,846.[1]
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Type I tyrosinemia from Other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications, and Prognosis
Natural History
Complications
Prognosis
Diagnosis
Diagnostic Criteria
History and Symptoms
Physical Examination
Laboratory Findings
Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
References
- ↑ Grompe M, St-Louis M, Demers SI, al-Dhalimy M, Leclerc B, Tanguay RM (1994). "A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I". N. Engl. J. Med. 331 (6): 353–7. PMID 8028615.